Labcorp outlines specialty testing growth, shares trade in tight NYSE range

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:46.

Labcorp (US50540R4092) sits in focus for US healthcare investors, with NYSE-listed shares recently changing hands around the mid-260 dollar area according to latest market data. Analyst commentary underlines specialty testing growth and a robust earnings profile versus the broader healthcare sector, as highlighted by Zacks and other research providers. Zacks analysis on Labcorp

Analysts see earnings strength

Zacks currently assigns Labcorp the equivalent of a Buy rating (Rank #2), pointing to a 6.9 percent earnings yield compared with roughly 4.3 percent for its healthcare diagnostics peer group. Zacks earnings yield comparison The research house notes that Labcorp has delivered an average earnings surprise of about 3.3 percent over the last four reported quarters, indicating consistent performance against Wall Street expectations. Zacks EPS surprise data

For 2026, the Zacks Consensus Estimate for Labcorp earnings per share has edged up in the past month to around 18.00 dollars, with the revenue consensus at roughly 14.71 billion dollars implying mid-single-digit growth year on year. Zacks 2026 EPS and revenue estimates Labcorp’s market capitalization stands a little above 21 billion dollars, placing the company firmly among mid-to-large healthcare providers in the US equity universe. Zacks market cap figures

What recent trading and technicals show

Labcorp shares most recently closed at about 266 dollars on the NYSE, with TradingKey data citing a close of 266.18 dollars on 25 June and a daily move of around 0.4 percent. TradingKey quote and daily move The same source places near-term support at roughly 254.6 dollars and resistance around 276.5 dollars, framing the stock in a defined trading corridor for range-oriented investors. TradingKey support and resistance

TradingKey’s technical overview describes Labcorp as showing three buy and one sell signal across its indicator set, with four buy and two sell readings across moving averages from 5-day to 200-day horizons. TradingKey technical summary The provider also assigns a price momentum score of 8.8, ranking the stock near the middle of the Healthcare Providers & Services cohort it tracks. TradingKey momentum score

How Labcorp generates its revenue

Labcorp generates most of its revenue from diagnostic testing services, operating a broad network of laboratories that process blood tests, pathology samples and other clinical diagnostics for physicians, hospitals and patients in the United States and internationally. Labcorp company information The company also runs a central laboratory and drug development business, providing testing and related services to pharmaceutical and biotech clients across the clinical trial lifecycle. Labcorp clinical trial services overview

Where the Labcorp shares trade today

The Labcorp shares (US50540R4092) most recently traded on the NYSE at around 266.18 US dollars as of 2026-06-25, 16:00 New York time, based on TradingKey data for the LH ticker. TradingKey latest NYSE close

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any form of financial promotion. All data are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research and consider their individual financial situation before making investment decisions.